Then we quantified the expression level of top eight circRNAs in cohort 2 that included sixteen HER2+ BC patients who were sensitive to trastuzumab HER2+ BC patients and fifty-five resistant to trastuzumab. Here, ERBB2 is linked to breast cancer.